Shattuck Labs Q2 net loss widens as R&D spending rises
STTK•Pipeline outlook
The company expects to initiate a Phase 2b trial of SL-325 in Crohn's disease in the third quarter of 2026, with primary endpoint data from the trial expected in the first half of 2028.
Shattuck said higher R&D expenses reflected progress advancing its clinical pipeline. It also cited favorable safety and immunogenicity profiles and durable DR3 blockade from the Phase 1 trial of SL-325.
The company announced progress on SL-846, a bispecific antibody, with preclinical and clinical data expected.
Reported quarterly figures
| Metric | Actual |
|---|---|
| Q2 net loss | $15.15 million |
| Q2 income from operations | -$16.16 million |
| Q2 loss per basic share | $0.12 |
The current average analyst rating on the shares is buy, with 10 strong buy or buy ratings, no hold ratings, and no sell or strong sell ratings.
Wall Street's median 12-month price target for Shattuck Labs Inc is $16.50, about 131.1% above its Aug. 10 closing price of $7.14.
